Rob has worked in the area of securities law, corporate finance, venture capital and mergers & acquisitions since 1998. Prior to joining THP, he worked in Citigroup Global Markets’ San Francisco office focused on healthcare investment banking and acquisition finance. Previously, Rob worked at the Securities & Exchange Commission in Los Angeles and the New York-based law firm of Cravath, Swaine & Moore. Rob also served as a Peace Corps Volunteer in the Dominican Republic. Rob has represented THP on the boards of InvisALERT, MedPricer (acquired by Premier), Nimble Therapeutics, Nivagen, TrakCel, and Verogen and he has been a board observer at Akoya Biosciences (NASDAQ:AKYA), Freedom Innovations (acquired by Health Evolution Partners) and Specific Diagnostics (acquired by bioMérieux). Rob received a BS in Geological Sciences and a BA in Economics from UCSB. He received a JD/MBA from Northwestern University School of Law and Kellogg School of Management.